{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:55:17Z","timestamp":1787968517707,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.intimp.2025.114096","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:39:58Z","timestamp":1737725998000},"page":"114096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Expression and correlation analysis of VISTA in peripheral blood mononuclear cells of myasthenia gravis patients"],"prefix":"10.1016","volume":"148","author":[{"given":"Yan","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiteng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-3264","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-065X.1998.tb01217.x","article-title":"Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis","volume":"164","author":"Vincent","year":"1998","journal-title":"Immunological reviews"},{"issue":"10","key":"10.1016\/j.intimp.2025.114096_b0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2025.114096_b0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jneuroim.2004.04.021","article-title":"Dendritic cells activate autologous T cells and induce IL-4 and IL-10 production in myasthenia gravis","volume":"156","author":"Adikari","year":"2004","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.intimp.2025.114096_b0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2025.114096_b0030","article-title":"Dendritic cell subsets and locations","volume":"348","author":"Sreekumar","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.intimp.2025.114096_b0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.184.2.349","article-title":"Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis","volume":"184","author":"Zhang","year":"1996","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13563","article-title":"Challenging the current model of early-onset myasthenia gravis pathogenesis in the light of the MGTX trial and histological heterogeneity of thymectomy specimens","volume":"1413","author":"Weis","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T cells in multiple sclerosis and myasthenia gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0050","article-title":"Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis","volume":"23","author":"Xiao","year":"2022","journal-title":"BMC Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2025.114096_b0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1084\/jem.181.2.547","article-title":"Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction","volume":"181","author":"Gu","year":"1995","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.intimp.2025.114096_b0060","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1084\/jem.164.6.2113","article-title":"Gamma interferon enhances macrophage transcription of the tumor necrosis factor\/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors","volume":"164","author":"Collart","year":"1986","journal-title":"J Exp Med"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2025.114096_b0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0165-5728(97)00161-6","article-title":"Polymorphisms in IL-1\u03b2 and IL-1 receptor antagonist genes are associated with myasthenia gravis","volume":"81","author":"Huang","year":"1998","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.intimp.2025.114096_b0070","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2249.1996.50755.x","article-title":"Cellular mRNA expression of interferon-gamma (IFN-\u03b3), IL-4 and transforming growth factor-beta (TGF-\u03b2) in rats nasally tolerized against experimental autoimmune myasthenia gravis (EAMG)","volume":"104","author":"Ma","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2025.114096_b0075","article-title":"Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis","volume":"19","author":"Rui-Sheng","year":"2002","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1172\/JCI118398","article-title":"Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice","volume":"97","author":"Tsujinaka","year":"1996","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.intimp.2025.114096_b0085","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Muthusamy","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2025.114096_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940930","article-title":"The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic\/Diagnostic Levers","volume":"13","author":"Hensler","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.intimp.2025.114096_b0095","article-title":"Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals","volume":"9","author":"Preeti","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.intimp.2025.114096_b0100","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2025.114096_b0105","article-title":"Expression and function of VISTA on myeloid cells","volume":"222","author":"Siyu","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.intimp.2025.114096_b0110","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201601","article-title":"VISTA is an activating receptor in human monocytes","volume":"218","author":"Rogers","year":"2021","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.intimp.2025.114096_b0115","article-title":"The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation","volume":"15","author":"Wenwen","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.intimp.2025.114096_b0120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG\u2010ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"issue":"522","key":"10.1016\/j.intimp.2025.114096_b0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1159","article-title":"PD-1H (VISTA)\u2013mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus","volume":"11","author":"Han","year":"2019","journal-title":"Science translational medicine"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13075-017-1474-y","article-title":"VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes","volume":"19","author":"Ceeraz","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.intimp.2025.114096_b0135","article-title":"VISTA-Ig ameliorates OXA-induced allergic dermatitis symptoms in mice","volume":"43","author":"Yuying","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0140","article-title":"Altered serum levels of cytokines in patients with myasthenia gravis","volume":"10","author":"Shu-Li","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.intimp.2025.114096_b0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clinical immunology"},{"issue":"3","key":"10.1016\/j.intimp.2025.114096_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36740\/WLek202103117","article-title":"Genomic and epigenomic predictors for various clinical phenotypes of myasthenia gravis","volume":"74","author":"Klimova","year":"2021","journal-title":"Wiad Lek"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0155","article-title":"Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10","volume":"164","author":"Wenling","year":"2019","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"1","key":"10.1016\/j.intimp.2025.114096_b0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-510X(98)00181-6","article-title":"Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis","volume":"161","author":"Li","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.intimp.2025.114096_b0165","article-title":"CD4(+) FoxP3(+) T regulatory cell subsets in myasthenia gravis patients","volume":"179","author":"Siegfried","year":"2017","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2025.114096_b0170","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/art.40020","article-title":"VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis","volume":"69","author":"Ceeraz","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.intimp.2025.114096_b0175","article-title":"A VISTA on PD-1H","volume":"124","author":"Yang","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.intimp.2025.114096_b0180","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Li","year":"2011","journal-title":"J Exp Med"},{"issue":"41","key":"10.1016\/j.intimp.2025.114096_b0185","article-title":"Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity","volume":"111","author":"Li","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.intimp.2025.114096_b0190","article-title":"VISTA facilitates phagocytic clearance of HIV infected CEM-SS T cells","volume":"7","author":"Xuequn","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2025.114096_b0195","article-title":"Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort","volume":"69","author":"Gao-Mei","year":"2019","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.intimp.2025.114096_b0200","article-title":"Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis","volume":"193","author":"Priya","year":"2007","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1016\/j.intimp.2025.114096_b0205","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2025.114096_b0210","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.3c00129","article-title":"Tumor-Derived PD-L1+ Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment","author":"Jia","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"20","key":"10.1016\/j.intimp.2025.114096_b0215","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:59:07Z","timestamp":1740617947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"alternative-id":["S1567576925000852"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114096","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression and correlation analysis of VISTA in peripheral blood mononuclear cells of myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114096"}}